Creative Medical wins FDA clearance to expand ADAPT trial of Olastrocel in chronic lower back pain

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc.

CELZ

0.00
  • Creative Medical Technology Holdings expanded its FDA-cleared ADAPT trial of CELZ-201 (Olastrocel) in chronic lower back pain tied to degenerative disc disease.
  • New protocol adds 15 patients using under 90 mg/day morphine equivalents; enrollment is over 85% with completion targeted before end of summer 2026.
  • Interim 180-day results were already presented, showing meaningful improvements in pain and function with a favorable safety profile.
  • Expansion uses an AI-based monitoring system to track patient-reported outcomes and analgesic use, aiming to strengthen the dataset for regulatory planning.
  • Phase 3 planning discussions with the FDA are being prepared, targeting a broader chronic lower back pain indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220915PRIMZONEFULLFEED9750144) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.